The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms.


Journal

The journal of investigative dermatology. Symposium proceedings
ISSN: 1529-1774
Titre abrégé: J Investig Dermatol Symp Proc
Pays: United States
ID NLM: 9609059

Informations de publication

Date de publication:
11 2020
Historique:
entrez: 25 10 2020
pubmed: 26 10 2020
medline: 24 9 2021
Statut: ppublish

Résumé

Meaningful patient input to understand disease experience and patient expectations for improvement with treatment is essential for the selection and development of outcome measures for alopecia areata (AA) clinical trials. This study explored the physical signs and symptoms of AA through 30 semistructured interviews with adult (n = 25) and adolescent (n = 5) patients experienced with severe or very severe AA. Scalp hair loss was overwhelmingly the most important sign and symptom of AA. Nearly all patients (90%) considered scalp hair loss in their top three most bothersome physical signs and symptoms of AA, with 77% (n = 23) naming scalp hair loss as the most bothersome symptom. Other identified signs and symptoms in the top three most bothersome included eyebrow, eyelash, nose, body, and facial hair loss, as well as eye irritation and nail damage and/or appearance. Eyebrow (16%, n = 4), eyelash (4%, n = 1), nasal (4%, n = 1), and body (4%, n = 1) hair loss were identified by seven adult patients as the most bothersome signs and symptoms of AA. Conceptual saturation confirmed that a comprehensive understanding of this patient population's physical AA-related signs and symptoms was obtained. These findings indicate that the primary objective for new AA treatments for this patient population should be meaningful improvement in scalp hair growth to address the most troubling unmet need.

Identifiants

pubmed: 33099392
pii: S1087-0024(20)30016-2
doi: 10.1016/j.jisp.2020.05.006
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

S71-S77

Subventions

Organisme : NIAMS NIH HHS
ID : R13 AR074890
Pays : United States

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Kathleen W Wyrwich (KW)

Patient-Centered Outcomes Assessment, Pfizer Inc, New York, New York, USA. Electronic address: kathy.wyrwich@gmail.com.

Helen Kitchen (H)

Clinical Outcomes Assessment, DRG Abacus, Manchester, United Kingdom.

Sarah Knight (S)

Clinical Outcomes Assessment, DRG Abacus, Manchester, United Kingdom.

Natalie V J Aldhouse (NVJ)

Clinical Outcomes Assessment, DRG Abacus, Manchester, United Kingdom.

Jake Macey (J)

Clinical Outcomes Assessment, DRG Abacus, Manchester, United Kingdom.

Fabio Nunes (F)

Lilly Biomedicines, Eli Lilly and Company, Indianapolis, Indiana, USA.

Yves Dutronc (Y)

Lilly Biomedicines, Eli Lilly and Company, Indianapolis, Indiana, USA.

Natasha A Mesinkovska (NA)

Department of Dermatology, University of California Irvine, Irvine, California, USA.

Justin M Ko (JM)

Department of Dermatology, Stanford University School of Medicine, Redwood City, California, USA.

Brett A King (BA)

Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH